Global Antibody Validation Market

Antibody Validation Comprehensive Study by Type (Standard Antibody Validation, Enhanced Antibody Validation), Antibodies (IgG, IgM, IgA, IgD, IgE), Assays (Western blot (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF), ELISA, Immunoprecipitation (IP), Others) Players and Region - Global Market Outlook to 2026

Antibody Validation Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Antibody Validation Market Overview:
According to the United States FDA, antibody validation is “The process of demonstrating, through the use of specific laboratory investigations, that the performance characteristics of an analytical method are suitable for its intended analytical use.” The performance characteristics may include: proving specificity, proving affinity, and proving reproducibility. Antibodies are used as reagents in life science researches, diagnostics, and clinical tests. Even though their use is widespread use in many areas and a huge investment of time and money for it; there is a lack of guidelines that define how they should be validated before use. Which causes a waste of a lot of time and money. Due to the lack of governing agency for antibody validation; several antibody selling companies are reluctant to validate them. But with a rapidly growing business, validating antibodies is seen as a competitive advantage.

Growth Drivers
  • Increasing Demand for Antibody Validation to Check Performance Prior to Their Use
  • Growing Use of Antibodies in Treating Immune Deficiencies

Market Trends
  • Introduction of Antibody Validation to Reduce Waste of Time and Money
  • Increasing Use of Specialised Type of Antibody Validation for Different Applications

Roadblocks
  • Concerns About Widespread Implementation of Standardized Process of Antibody Validation

Opportunities
  • Surging Demand for Antibody Validation Due to Increasing Use of Antibodies in Biomedical Research

Challenges
  • Antibody Performance Can Vary Beyond Validation Efforts Like Shipping and Transportation
  • Some Antibody Validation Techniques Require Specialized Equipment


Competitive Landscape:
This market is fragmented among the various regions. The antibody validation market is in the growth phase and has a lot of potential with the increasing use of antibodies. With increasing realization among end-users about the inconsistent quality of antibodies the demand is set to increase for antibody validation. High expertise is required to operate in this market. Also, high R&D cost is required along with capita expenses. There is an opportunity in this market for mergers and acquisitions to increase revenue and R&D capabilities.
Some of the key players profiled in the report are Moderna (United States), Merck (United States), GenScript (United States), Creative Diagnostics (United States), Boster (United States), Abcam (United Kingdom), Cell Signalling Technology (United States), Thermo Fisher Scientific (United States), Bio-Rad Laboratories (United States) and Invitrogen (United States). Additionally, following companies can also be profiled that are part of our coverage like Novus Biologicals (United States), Lifespan Biosciences (United States), OriGene (United States) and Amgen (United States). Considering Market by Antibodies, the sub-segment i.e. IgG will boost the Antibody Validation market. Considering Market by Assays, the sub-segment i.e. Western blot (WB) will boost the Antibody Validation market.



What Can be Explored with the Antibody Validation Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Antibody Validation Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Antibody Validation
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Antibody Validation market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Antibody Validation market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Antibody Validation Providers, Raw Material Suppliers, Government Regulatory and Research Organizations, End-Use Industries and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Standard Antibody Validation
  • Enhanced Antibody Validation
By Antibodies
  • IgG
  • IgM
  • IgA
  • IgD
  • IgE

By Assays
  • Western blot (WB)
  • Immunohistochemistry (IHC)
  • Immunocytochemistry (ICC)
  • Immunofluorescence (IF)
  • ELISA
  • Immunoprecipitation (IP)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand for Antibody Validation to Check Performance Prior to Their Use
      • 3.2.2. Growing Use of Antibodies in Treating Immune Deficiencies
    • 3.3. Market Challenges
      • 3.3.1. Antibody Performance Can Vary Beyond Validation Efforts Like Shipping and Transportation
      • 3.3.2. Some Antibody Validation Techniques Require Specialized Equipment
    • 3.4. Market Trends
      • 3.4.1. Introduction of Antibody Validation to Reduce Waste of Time and Money
      • 3.4.2. Increasing Use of Specialised Type of Antibody Validation for Different Applications
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antibody Validation, by Type, Antibodies, Assays and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Antibody Validation (Value)
      • 5.2.1. Global Antibody Validation by: Type (Value)
        • 5.2.1.1. Standard Antibody Validation
        • 5.2.1.2. Enhanced Antibody Validation
      • 5.2.2. Global Antibody Validation by: Antibodies (Value)
        • 5.2.2.1. IgG
        • 5.2.2.2. IgM
        • 5.2.2.3. IgA
        • 5.2.2.4. IgD
        • 5.2.2.5. IgE
      • 5.2.3. Global Antibody Validation by: Assays (Value)
        • 5.2.3.1. Western blot (WB)
        • 5.2.3.2. Immunohistochemistry (IHC)
        • 5.2.3.3. Immunocytochemistry (ICC)
        • 5.2.3.4. Immunofluorescence (IF)
        • 5.2.3.5. ELISA
        • 5.2.3.6. Immunoprecipitation (IP)
        • 5.2.3.7. Others
      • 5.2.4. Global Antibody Validation Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Antibody Validation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Moderna (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GenScript (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Creative Diagnostics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Boster (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abcam (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cell Signalling Technology (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Thermo Fisher Scientific (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bio-Rad Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Invitrogen (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antibody Validation Sale, by Type, Antibodies, Assays and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Antibody Validation (Value)
      • 7.2.1. Global Antibody Validation by: Type (Value)
        • 7.2.1.1. Standard Antibody Validation
        • 7.2.1.2. Enhanced Antibody Validation
      • 7.2.2. Global Antibody Validation by: Antibodies (Value)
        • 7.2.2.1. IgG
        • 7.2.2.2. IgM
        • 7.2.2.3. IgA
        • 7.2.2.4. IgD
        • 7.2.2.5. IgE
      • 7.2.3. Global Antibody Validation by: Assays (Value)
        • 7.2.3.1. Western blot (WB)
        • 7.2.3.2. Immunohistochemistry (IHC)
        • 7.2.3.3. Immunocytochemistry (ICC)
        • 7.2.3.4. Immunofluorescence (IF)
        • 7.2.3.5. ELISA
        • 7.2.3.6. Immunoprecipitation (IP)
        • 7.2.3.7. Others
      • 7.2.4. Global Antibody Validation Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antibody Validation: by Type(USD Million)
  • Table 2. Antibody Validation Standard Antibody Validation , by Region USD Million (2015-2020)
  • Table 3. Antibody Validation Enhanced Antibody Validation , by Region USD Million (2015-2020)
  • Table 4. Antibody Validation: by Antibodies(USD Million)
  • Table 5. Antibody Validation IgG , by Region USD Million (2015-2020)
  • Table 6. Antibody Validation IgM , by Region USD Million (2015-2020)
  • Table 7. Antibody Validation IgA , by Region USD Million (2015-2020)
  • Table 8. Antibody Validation IgD , by Region USD Million (2015-2020)
  • Table 9. Antibody Validation IgE , by Region USD Million (2015-2020)
  • Table 10. Antibody Validation: by Assays(USD Million)
  • Table 11. Antibody Validation Western blot (WB) , by Region USD Million (2015-2020)
  • Table 12. Antibody Validation Immunohistochemistry (IHC) , by Region USD Million (2015-2020)
  • Table 13. Antibody Validation Immunocytochemistry (ICC) , by Region USD Million (2015-2020)
  • Table 14. Antibody Validation Immunofluorescence (IF) , by Region USD Million (2015-2020)
  • Table 15. Antibody Validation ELISA , by Region USD Million (2015-2020)
  • Table 16. Antibody Validation Immunoprecipitation (IP) , by Region USD Million (2015-2020)
  • Table 17. Antibody Validation Others , by Region USD Million (2015-2020)
  • Table 18. South America Antibody Validation, by Country USD Million (2015-2020)
  • Table 19. South America Antibody Validation, by Type USD Million (2015-2020)
  • Table 20. South America Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 21. South America Antibody Validation, by Assays USD Million (2015-2020)
  • Table 22. Brazil Antibody Validation, by Type USD Million (2015-2020)
  • Table 23. Brazil Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 24. Brazil Antibody Validation, by Assays USD Million (2015-2020)
  • Table 25. Argentina Antibody Validation, by Type USD Million (2015-2020)
  • Table 26. Argentina Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 27. Argentina Antibody Validation, by Assays USD Million (2015-2020)
  • Table 28. Rest of South America Antibody Validation, by Type USD Million (2015-2020)
  • Table 29. Rest of South America Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 30. Rest of South America Antibody Validation, by Assays USD Million (2015-2020)
  • Table 31. Asia Pacific Antibody Validation, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Antibody Validation, by Type USD Million (2015-2020)
  • Table 33. Asia Pacific Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 34. Asia Pacific Antibody Validation, by Assays USD Million (2015-2020)
  • Table 35. China Antibody Validation, by Type USD Million (2015-2020)
  • Table 36. China Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 37. China Antibody Validation, by Assays USD Million (2015-2020)
  • Table 38. Japan Antibody Validation, by Type USD Million (2015-2020)
  • Table 39. Japan Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 40. Japan Antibody Validation, by Assays USD Million (2015-2020)
  • Table 41. India Antibody Validation, by Type USD Million (2015-2020)
  • Table 42. India Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 43. India Antibody Validation, by Assays USD Million (2015-2020)
  • Table 44. South Korea Antibody Validation, by Type USD Million (2015-2020)
  • Table 45. South Korea Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 46. South Korea Antibody Validation, by Assays USD Million (2015-2020)
  • Table 47. Taiwan Antibody Validation, by Type USD Million (2015-2020)
  • Table 48. Taiwan Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 49. Taiwan Antibody Validation, by Assays USD Million (2015-2020)
  • Table 50. Australia Antibody Validation, by Type USD Million (2015-2020)
  • Table 51. Australia Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 52. Australia Antibody Validation, by Assays USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Antibody Validation, by Type USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Antibody Validation, by Assays USD Million (2015-2020)
  • Table 56. Europe Antibody Validation, by Country USD Million (2015-2020)
  • Table 57. Europe Antibody Validation, by Type USD Million (2015-2020)
  • Table 58. Europe Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 59. Europe Antibody Validation, by Assays USD Million (2015-2020)
  • Table 60. Germany Antibody Validation, by Type USD Million (2015-2020)
  • Table 61. Germany Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 62. Germany Antibody Validation, by Assays USD Million (2015-2020)
  • Table 63. France Antibody Validation, by Type USD Million (2015-2020)
  • Table 64. France Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 65. France Antibody Validation, by Assays USD Million (2015-2020)
  • Table 66. Italy Antibody Validation, by Type USD Million (2015-2020)
  • Table 67. Italy Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 68. Italy Antibody Validation, by Assays USD Million (2015-2020)
  • Table 69. United Kingdom Antibody Validation, by Type USD Million (2015-2020)
  • Table 70. United Kingdom Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 71. United Kingdom Antibody Validation, by Assays USD Million (2015-2020)
  • Table 72. Netherlands Antibody Validation, by Type USD Million (2015-2020)
  • Table 73. Netherlands Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 74. Netherlands Antibody Validation, by Assays USD Million (2015-2020)
  • Table 75. Rest of Europe Antibody Validation, by Type USD Million (2015-2020)
  • Table 76. Rest of Europe Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 77. Rest of Europe Antibody Validation, by Assays USD Million (2015-2020)
  • Table 78. MEA Antibody Validation, by Country USD Million (2015-2020)
  • Table 79. MEA Antibody Validation, by Type USD Million (2015-2020)
  • Table 80. MEA Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 81. MEA Antibody Validation, by Assays USD Million (2015-2020)
  • Table 82. Middle East Antibody Validation, by Type USD Million (2015-2020)
  • Table 83. Middle East Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 84. Middle East Antibody Validation, by Assays USD Million (2015-2020)
  • Table 85. Africa Antibody Validation, by Type USD Million (2015-2020)
  • Table 86. Africa Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 87. Africa Antibody Validation, by Assays USD Million (2015-2020)
  • Table 88. North America Antibody Validation, by Country USD Million (2015-2020)
  • Table 89. North America Antibody Validation, by Type USD Million (2015-2020)
  • Table 90. North America Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 91. North America Antibody Validation, by Assays USD Million (2015-2020)
  • Table 92. United States Antibody Validation, by Type USD Million (2015-2020)
  • Table 93. United States Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 94. United States Antibody Validation, by Assays USD Million (2015-2020)
  • Table 95. Canada Antibody Validation, by Type USD Million (2015-2020)
  • Table 96. Canada Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 97. Canada Antibody Validation, by Assays USD Million (2015-2020)
  • Table 98. Mexico Antibody Validation, by Type USD Million (2015-2020)
  • Table 99. Mexico Antibody Validation, by Antibodies USD Million (2015-2020)
  • Table 100. Mexico Antibody Validation, by Assays USD Million (2015-2020)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Antibody Validation: by Type(USD Million)
  • Table 112. Antibody Validation Standard Antibody Validation , by Region USD Million (2021-2026)
  • Table 113. Antibody Validation Enhanced Antibody Validation , by Region USD Million (2021-2026)
  • Table 114. Antibody Validation: by Antibodies(USD Million)
  • Table 115. Antibody Validation IgG , by Region USD Million (2021-2026)
  • Table 116. Antibody Validation IgM , by Region USD Million (2021-2026)
  • Table 117. Antibody Validation IgA , by Region USD Million (2021-2026)
  • Table 118. Antibody Validation IgD , by Region USD Million (2021-2026)
  • Table 119. Antibody Validation IgE , by Region USD Million (2021-2026)
  • Table 120. Antibody Validation: by Assays(USD Million)
  • Table 121. Antibody Validation Western blot (WB) , by Region USD Million (2021-2026)
  • Table 122. Antibody Validation Immunohistochemistry (IHC) , by Region USD Million (2021-2026)
  • Table 123. Antibody Validation Immunocytochemistry (ICC) , by Region USD Million (2021-2026)
  • Table 124. Antibody Validation Immunofluorescence (IF) , by Region USD Million (2021-2026)
  • Table 125. Antibody Validation ELISA , by Region USD Million (2021-2026)
  • Table 126. Antibody Validation Immunoprecipitation (IP) , by Region USD Million (2021-2026)
  • Table 127. Antibody Validation Others , by Region USD Million (2021-2026)
  • Table 128. South America Antibody Validation, by Country USD Million (2021-2026)
  • Table 129. South America Antibody Validation, by Type USD Million (2021-2026)
  • Table 130. South America Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 131. South America Antibody Validation, by Assays USD Million (2021-2026)
  • Table 132. Brazil Antibody Validation, by Type USD Million (2021-2026)
  • Table 133. Brazil Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 134. Brazil Antibody Validation, by Assays USD Million (2021-2026)
  • Table 135. Argentina Antibody Validation, by Type USD Million (2021-2026)
  • Table 136. Argentina Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 137. Argentina Antibody Validation, by Assays USD Million (2021-2026)
  • Table 138. Rest of South America Antibody Validation, by Type USD Million (2021-2026)
  • Table 139. Rest of South America Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 140. Rest of South America Antibody Validation, by Assays USD Million (2021-2026)
  • Table 141. Asia Pacific Antibody Validation, by Country USD Million (2021-2026)
  • Table 142. Asia Pacific Antibody Validation, by Type USD Million (2021-2026)
  • Table 143. Asia Pacific Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 144. Asia Pacific Antibody Validation, by Assays USD Million (2021-2026)
  • Table 145. China Antibody Validation, by Type USD Million (2021-2026)
  • Table 146. China Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 147. China Antibody Validation, by Assays USD Million (2021-2026)
  • Table 148. Japan Antibody Validation, by Type USD Million (2021-2026)
  • Table 149. Japan Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 150. Japan Antibody Validation, by Assays USD Million (2021-2026)
  • Table 151. India Antibody Validation, by Type USD Million (2021-2026)
  • Table 152. India Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 153. India Antibody Validation, by Assays USD Million (2021-2026)
  • Table 154. South Korea Antibody Validation, by Type USD Million (2021-2026)
  • Table 155. South Korea Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 156. South Korea Antibody Validation, by Assays USD Million (2021-2026)
  • Table 157. Taiwan Antibody Validation, by Type USD Million (2021-2026)
  • Table 158. Taiwan Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 159. Taiwan Antibody Validation, by Assays USD Million (2021-2026)
  • Table 160. Australia Antibody Validation, by Type USD Million (2021-2026)
  • Table 161. Australia Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 162. Australia Antibody Validation, by Assays USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Antibody Validation, by Type USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Antibody Validation, by Assays USD Million (2021-2026)
  • Table 166. Europe Antibody Validation, by Country USD Million (2021-2026)
  • Table 167. Europe Antibody Validation, by Type USD Million (2021-2026)
  • Table 168. Europe Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 169. Europe Antibody Validation, by Assays USD Million (2021-2026)
  • Table 170. Germany Antibody Validation, by Type USD Million (2021-2026)
  • Table 171. Germany Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 172. Germany Antibody Validation, by Assays USD Million (2021-2026)
  • Table 173. France Antibody Validation, by Type USD Million (2021-2026)
  • Table 174. France Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 175. France Antibody Validation, by Assays USD Million (2021-2026)
  • Table 176. Italy Antibody Validation, by Type USD Million (2021-2026)
  • Table 177. Italy Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 178. Italy Antibody Validation, by Assays USD Million (2021-2026)
  • Table 179. United Kingdom Antibody Validation, by Type USD Million (2021-2026)
  • Table 180. United Kingdom Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 181. United Kingdom Antibody Validation, by Assays USD Million (2021-2026)
  • Table 182. Netherlands Antibody Validation, by Type USD Million (2021-2026)
  • Table 183. Netherlands Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 184. Netherlands Antibody Validation, by Assays USD Million (2021-2026)
  • Table 185. Rest of Europe Antibody Validation, by Type USD Million (2021-2026)
  • Table 186. Rest of Europe Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 187. Rest of Europe Antibody Validation, by Assays USD Million (2021-2026)
  • Table 188. MEA Antibody Validation, by Country USD Million (2021-2026)
  • Table 189. MEA Antibody Validation, by Type USD Million (2021-2026)
  • Table 190. MEA Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 191. MEA Antibody Validation, by Assays USD Million (2021-2026)
  • Table 192. Middle East Antibody Validation, by Type USD Million (2021-2026)
  • Table 193. Middle East Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 194. Middle East Antibody Validation, by Assays USD Million (2021-2026)
  • Table 195. Africa Antibody Validation, by Type USD Million (2021-2026)
  • Table 196. Africa Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 197. Africa Antibody Validation, by Assays USD Million (2021-2026)
  • Table 198. North America Antibody Validation, by Country USD Million (2021-2026)
  • Table 199. North America Antibody Validation, by Type USD Million (2021-2026)
  • Table 200. North America Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 201. North America Antibody Validation, by Assays USD Million (2021-2026)
  • Table 202. United States Antibody Validation, by Type USD Million (2021-2026)
  • Table 203. United States Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 204. United States Antibody Validation, by Assays USD Million (2021-2026)
  • Table 205. Canada Antibody Validation, by Type USD Million (2021-2026)
  • Table 206. Canada Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 207. Canada Antibody Validation, by Assays USD Million (2021-2026)
  • Table 208. Mexico Antibody Validation, by Type USD Million (2021-2026)
  • Table 209. Mexico Antibody Validation, by Antibodies USD Million (2021-2026)
  • Table 210. Mexico Antibody Validation, by Assays USD Million (2021-2026)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antibody Validation: by Type USD Million (2015-2020)
  • Figure 5. Global Antibody Validation: by Antibodies USD Million (2015-2020)
  • Figure 6. Global Antibody Validation: by Assays USD Million (2015-2020)
  • Figure 7. South America Antibody Validation Share (%), by Country
  • Figure 8. Asia Pacific Antibody Validation Share (%), by Country
  • Figure 9. Europe Antibody Validation Share (%), by Country
  • Figure 10. MEA Antibody Validation Share (%), by Country
  • Figure 11. North America Antibody Validation Share (%), by Country
  • Figure 12. Global Antibody Validation share by Players 2020 (%)
  • Figure 13. Global Antibody Validation share by Players (Top 3) 2020(%)
  • Figure 14. Global Antibody Validation share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Moderna (United States) Revenue, Net Income and Gross profit
  • Figure 17. Moderna (United States) Revenue: by Geography 2020
  • Figure 18. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 19. Merck (United States) Revenue: by Geography 2020
  • Figure 20. GenScript (United States) Revenue, Net Income and Gross profit
  • Figure 21. GenScript (United States) Revenue: by Geography 2020
  • Figure 22. Creative Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 23. Creative Diagnostics (United States) Revenue: by Geography 2020
  • Figure 24. Boster (United States) Revenue, Net Income and Gross profit
  • Figure 25. Boster (United States) Revenue: by Geography 2020
  • Figure 26. Abcam (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. Abcam (United Kingdom) Revenue: by Geography 2020
  • Figure 28. Cell Signalling Technology (United States) Revenue, Net Income and Gross profit
  • Figure 29. Cell Signalling Technology (United States) Revenue: by Geography 2020
  • Figure 30. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 31. Thermo Fisher Scientific (United States) Revenue: by Geography 2020
  • Figure 32. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 33. Bio-Rad Laboratories (United States) Revenue: by Geography 2020
  • Figure 34. Invitrogen (United States) Revenue, Net Income and Gross profit
  • Figure 35. Invitrogen (United States) Revenue: by Geography 2020
  • Figure 36. Global Antibody Validation: by Type USD Million (2021-2026)
  • Figure 37. Global Antibody Validation: by Antibodies USD Million (2021-2026)
  • Figure 38. Global Antibody Validation: by Assays USD Million (2021-2026)
  • Figure 39. South America Antibody Validation Share (%), by Country
  • Figure 40. Asia Pacific Antibody Validation Share (%), by Country
  • Figure 41. Europe Antibody Validation Share (%), by Country
  • Figure 42. MEA Antibody Validation Share (%), by Country
  • Figure 43. North America Antibody Validation Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Moderna (United States)
  • Merck (United States)
  • GenScript (United States)
  • Creative Diagnostics (United States)
  • Boster (United States)
  • Abcam (United Kingdom)
  • Cell Signalling Technology (United States)
  • Thermo Fisher Scientific (United States)
  • Bio-Rad Laboratories (United States)
  • Invitrogen (United States)
Additional players considered in the study are as follows:
Novus Biologicals (United States) , Lifespan Biosciences (United States) , OriGene (United States) , Amgen (United States)
Select User Access Type

Key Highlights of Report


Mar 2021 234 Pages 72 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antibody Validation Market Quantitative research analysis
Global Antibody Validation Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Antibody Validation Market Report?

Have a Query? Click Here

Other Related Reports

RNase Control Comprehensive Study by Type (Positive Control, No Template Control), Application (Research Institutes, Laboratories, Health Institutes, Others), Function (RNA Cloning, CDNA Synthesis, E...
$ 3650
Globular Protein Comprehensive Study by Type (Recombinant Globular Protein, Bovine Globular Protein, Human Globular Protein), Application (Therapeutics, Vaccine, Other), End Use (Hospitals, Clinics) ...
$ 3500
Yeast Twohybrid System Comprehensive Study by Type (Protein-Protein Interaction, Protein-DNA Interaction), Application (Therapeutic, Industrial, Research), Form (Liquid, Tablet), Distribution Channel...
$ 3650
Biopharmaceutical Equipment Comprehensive Study by Type (Filtration Systems, Bioreactors, Extractors, Chromatography, Cell Culture, Bioprocessing Containers, Sterilizers, Others), Application (Biopro...
$ 3450
Algal Protein Expression System Comprehensive Study by Type (Reagents and Kits, Expression Vectors, Competent Cells, Instruments, Others), Application (Medical Research Institutions, Hospitals, Speci...
$ 3650
Biotinylated Polyclonal Antibodies Comprehensive Study by Type (Primary Antibody, Secondary Antibody), Application (Immunocytochemistry (ICC), Immunoprecipitation (IP), Western Blot (WB), In Situ Hyb...
$ 3500